ClinicalTrials.gg

Program

vepugratinib

Also written as “Vepugratinib”, “LY3866288” and “[14C]-LY3866288”.

Its studies are mostly in Urinary Bladder Neoplasms · Carcinoma, Transitional Cell, led by Eli Lilly.

Furthest: phase 3, since Oct 9, 20255 company-led studies, 3 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly53 open or runningphase 3since Oct 9, 2025Nov 7, 2022Jun 2027phase 1 · NCT05614739

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2022First study: phase 1 study in Urinary Bladder NeoplasmsFirst studyNCT05614739 · 677 planned · United States, Australia, Canada and more
  2. Oct 11, 20242 phase 1 studies in HealthyNCT06641037, NCT06644378
  3. Oct 9, 2025Phase 3 study in Carcinoma, Transitional CellNCT07218380 · 450 planned · United States, Australia, Brazil and more
  4. Sep 15, 2026Phase 2 study in Urinary Bladder NeoplasmsNCT07827612 · 161 planned · United States

Ahead

  1. Jun 2027Primary completion: phase 1 study in Urinary Bladder NeoplasmsNCT05614739
  2. Jul 2028Primary completion: phase 2 study in Urinary Bladder NeoplasmsNCT07827612
  3. Oct 2029Primary completion: phase 3 study in Carcinoma, Transitional CellNCT07218380

TargetBeta

FGFR3 →read by rule
“An orally bioavailable, selective inhibitor of human fibroblast growth factor receptor 3 (FGFR3), ”NCIt, by rule

Other programs on FGFR3

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
masitinibruleAB Sciencephase 338
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
dabogratinibruletyra-biosciences-incphase 25
FGFR3/4 Inhibitor TYRA-430ruletyra-biosciences-incphase 11
Anti-FGFR3 Antibody-drug Conjugate BHV-1530rulebiohaven-therapeutics-ltdphase 11

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07827612Urinary Bladder Neoplasms · United States2Not yet recruitingJul 2028161
NCT07218380Carcinoma, Transitional Cell · United States, Australia, Brazil and more3RecruitingOct 2029450
NCT06644378Healthy · United States1CompletedJan 3, 202515
NCT06641037Healthy · United States1CompletedDec 2, 202415
NCT05614739Urinary Bladder Neoplasms · United States, Australia, Canada and more1RecruitingJun 2027677

How it is read

Names in the registry

  • “Vepugratinib”, 3 entries
  • “LY3866288”, 2 entries
  • “[14C]-LY3866288”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.